ROS1 Biomarkers
In the TRUST-II trial, 85 percent of ROS1 TKI-naïve NSCLC patients and 62 percent of TKI-pretreated patients responded to the next-generation ROS1 inhibitor.
Lung Cancer Groups Seek Public Comment on Updated Biomarker Testing Guidelines
Updated guidelines recommend certain biomarker tests for early- and late-stage lung cancer at the time of diagnosis.
China's NMPA Approves Zai Lab's Augtyro in ROS1-Positive NSCLC
In a Phase I/II trial, 38 percent of patients who had prior tyrosine kinase inhibitor treatment responded, while the response rate among those who were TKI-naïve was 79 percent.
AnHeart, Innovent File for Frontline ROS1-Positive NSCLC Taletrectinib Approval in China
China's NMPA will decide whether to approve the tyrosine kinase inhibitor in advanced ROS1-positive NSCLC patients who haven't received prior ROS1 inhibitors.
AnHeart Therapeutics, Innovent Biologics File for Taletrectinib NSCLC Approval in China
Chinese regulators accepted a new drug application for taletrectinib in pretreated non-small cell lung cancer patients whose tumors harbor ROS1 gene fusions.